Cargando…
Pan‐cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia
BACKGROUND: CD300s are a group of proteins playing vital roles in immune responses. However, much is yet to be elucidated regarding the expression patterns and clinical significances of CD300s in cancers. METHODS: In this study, we comprehensively investigated CD300s in a pan‐cancer manner using mul...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844665/ https://www.ncbi.nlm.nih.gov/pubmed/35642341 http://dx.doi.org/10.1002/cam4.4905 |
_version_ | 1784870703689891840 |
---|---|
author | Xu, Zi‐jun Jin, Ye Zhang, Xin‐long Xia, Pei‐hui Wen, Xiang‐mei Ma, Ji‐chun Lin, Jiang Qian, Jun |
author_facet | Xu, Zi‐jun Jin, Ye Zhang, Xin‐long Xia, Pei‐hui Wen, Xiang‐mei Ma, Ji‐chun Lin, Jiang Qian, Jun |
author_sort | Xu, Zi‐jun |
collection | PubMed |
description | BACKGROUND: CD300s are a group of proteins playing vital roles in immune responses. However, much is yet to be elucidated regarding the expression patterns and clinical significances of CD300s in cancers. METHODS: In this study, we comprehensively investigated CD300s in a pan‐cancer manner using multi‐omic data from The Cancer Genome Atlas. We also studied the relationship between CD300s and the immune landscape of AML. RESULTS: We found that CD300A‐CD300LF were generally overexpressed in tumors (especially AML), whereas CD300LG was more often downregulated. In AML, transactivation of CD300A was not mediated by genetic alterations but by histone modification. Survival analyses revealed that high CD300A‐CD300LF expression predicted poor outcome in AML patients; the prognostic value of CD300A was validated in seven independent datasets and a meta dataset including 1115 AML patients. Furthermore, we demonstrated that CD300A expression could add prognostic value in refining existing risk models in AML. Importantly, CD300A‐CD300LF expression was closely associated with T‐cell dysfunction score and could predict response to AML immunotherapy. Also, CD300A was found to be positively associated with HLA genes and critical immune checkpoints in AML, such as VISTA, CD86, CD200R1, Tim‐3, and the LILRB family genes. CONCLUSIONS: Our study demonstrated CD300s as potential prognostic biomarker and an ideal immunotherapy target in AML, which warrants future functional and clinical studies. |
format | Online Article Text |
id | pubmed-9844665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98446652023-01-24 Pan‐cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia Xu, Zi‐jun Jin, Ye Zhang, Xin‐long Xia, Pei‐hui Wen, Xiang‐mei Ma, Ji‐chun Lin, Jiang Qian, Jun Cancer Med Research Articles BACKGROUND: CD300s are a group of proteins playing vital roles in immune responses. However, much is yet to be elucidated regarding the expression patterns and clinical significances of CD300s in cancers. METHODS: In this study, we comprehensively investigated CD300s in a pan‐cancer manner using multi‐omic data from The Cancer Genome Atlas. We also studied the relationship between CD300s and the immune landscape of AML. RESULTS: We found that CD300A‐CD300LF were generally overexpressed in tumors (especially AML), whereas CD300LG was more often downregulated. In AML, transactivation of CD300A was not mediated by genetic alterations but by histone modification. Survival analyses revealed that high CD300A‐CD300LF expression predicted poor outcome in AML patients; the prognostic value of CD300A was validated in seven independent datasets and a meta dataset including 1115 AML patients. Furthermore, we demonstrated that CD300A expression could add prognostic value in refining existing risk models in AML. Importantly, CD300A‐CD300LF expression was closely associated with T‐cell dysfunction score and could predict response to AML immunotherapy. Also, CD300A was found to be positively associated with HLA genes and critical immune checkpoints in AML, such as VISTA, CD86, CD200R1, Tim‐3, and the LILRB family genes. CONCLUSIONS: Our study demonstrated CD300s as potential prognostic biomarker and an ideal immunotherapy target in AML, which warrants future functional and clinical studies. John Wiley and Sons Inc. 2022-05-31 /pmc/articles/PMC9844665/ /pubmed/35642341 http://dx.doi.org/10.1002/cam4.4905 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Xu, Zi‐jun Jin, Ye Zhang, Xin‐long Xia, Pei‐hui Wen, Xiang‐mei Ma, Ji‐chun Lin, Jiang Qian, Jun Pan‐cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia |
title | Pan‐cancer analysis identifies
CD300
molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia |
title_full | Pan‐cancer analysis identifies
CD300
molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia |
title_fullStr | Pan‐cancer analysis identifies
CD300
molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia |
title_full_unstemmed | Pan‐cancer analysis identifies
CD300
molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia |
title_short | Pan‐cancer analysis identifies
CD300
molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia |
title_sort | pan‐cancer analysis identifies
cd300
molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844665/ https://www.ncbi.nlm.nih.gov/pubmed/35642341 http://dx.doi.org/10.1002/cam4.4905 |
work_keys_str_mv | AT xuzijun pancanceranalysisidentifiescd300moleculesaspotentialimmuneregulatorsandpromisingtherapeutictargetsinacutemyeloidleukemia AT jinye pancanceranalysisidentifiescd300moleculesaspotentialimmuneregulatorsandpromisingtherapeutictargetsinacutemyeloidleukemia AT zhangxinlong pancanceranalysisidentifiescd300moleculesaspotentialimmuneregulatorsandpromisingtherapeutictargetsinacutemyeloidleukemia AT xiapeihui pancanceranalysisidentifiescd300moleculesaspotentialimmuneregulatorsandpromisingtherapeutictargetsinacutemyeloidleukemia AT wenxiangmei pancanceranalysisidentifiescd300moleculesaspotentialimmuneregulatorsandpromisingtherapeutictargetsinacutemyeloidleukemia AT majichun pancanceranalysisidentifiescd300moleculesaspotentialimmuneregulatorsandpromisingtherapeutictargetsinacutemyeloidleukemia AT linjiang pancanceranalysisidentifiescd300moleculesaspotentialimmuneregulatorsandpromisingtherapeutictargetsinacutemyeloidleukemia AT qianjun pancanceranalysisidentifiescd300moleculesaspotentialimmuneregulatorsandpromisingtherapeutictargetsinacutemyeloidleukemia |